A genome-wide CRISPR screen identified FOXJ3 as a ferroptosis regulator in hepatocellular carcinoma, linking FOXJ3 to tumor progression through an OTUD5-mediated stabilization of GSTP1. The study positions ferroptosis suppression as a mechanistic axis for HCC survival and growth. By mapping the pathway, the work connects gene editing results to a defined molecular mechanism—GSTP1 stabilization via OTUD5—rather than an association-only signature. That provides more direct targets for follow-up drug discovery and makes it easier to imagine biomarker-driven patient selection. For oncology development teams, the signal is actionable: FOXJ3–OTUD5–GSTP1 forms a testable therapeutic chain where combining ferroptosis-inducing approaches with pathway inhibition could be evaluated in preclinical and translational studies.